First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.
Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yunben Yang(Zhejiang Cancer Hospital), Lei Zhang(Zhejiang Cancer Hospital), Jingjing Li(Zhejiang Cancer Hospital), Qi Xu(China Jiliang University), Meifang Zheng, Qing Wei(Chinese Academy of Sciences), Shurui Zhou(Zhejiang Cancer Hospital)
Cited by 1
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412